Navigation Links
CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Date:11/7/2007

Relations

T: +32-2-559-9414

antje.witte@ucb-group.com

Mareike Mohr, Investor Relations

T: +32-2-559-9264

mareike.mohr@ucb-group.com

Notes to Editors:

RAPID Clinical Trials Program

The RAPID series of clinical trials were designed to establish the efficacy and tolerability of CIMZIA(R) (certolizumab pegol) in the treatment of rheumatoid arthritis. The RAPID clinical trial program is comprised of two large, international, multi-center placebo-controlled studies - RAPID 1 (027) and RAPID 2 (050).

In the year-long RAPID 1 trial, 982 patients were randomly allocated to receive one of three treatment regimens:

-- 393 patients received 400 mg formulation CIMZIA at the start of the

study and at weeks two and four, then 200 mg given every two weeks,

together with methotrexate;

-- 390 patients received 400 mg formulation CIMZIA every two weeks,

together with methotrexate;

-- 199 patients received placebo every two weeks, together with

methotrexate.

In all three arms of the study, the dose of methotrexate was 10 mg per week or greater. Co-primary endpoints for the study RAPID 1 were the ACR20 responder rate(a) at week 24 and the change from baseline in mTSS(b) at week 52.

Six and 12 month ACR responses for RAPID 1

CIMZIA(R) CIMZIA(R)

(certolizumab (certolizumab

pegol) pegol)

Placebo & MTX 200mg & MTX 400mg & MTX

Six months

ACR 20 13.6 58.8 60.8*

ACR 50 7.6 37.1* 39.9*

ACR 70 3.0 21.4* 20.6*

12 months

ACR 20 13.1 53.1* 54.9*

'/>"/>
SOURCE UCB
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SAN DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... ended June 30, 2015.  Revenue for the quarter was ... quarter ended June 30, 2014 (a 17 percent increase ... million, consistent with the quarter ended June 30, 2014. ... consistent with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of ... to remind you about some of our Medicare resources and continue highlighting the success ... Check out our latest infographics and videos here: ... ... ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19
... tells her story but sometimes showing a few less chapters ... quest continues for new ways to keep skin looking its ... survey commissioned by Ulthera ® (the manufacturer of the ... a non-invasive lift indication), 83 percent of women admitted they ...
... Boston Scientific Corporation (NYSE: BSX ) today ... the 60th Annual Scientific Session of the American College ... "Twelve-month results from the PLATINUM Workhorse clinical ... Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to ...
Cached Medicine Technology:What Would Women Give Up for a More Youthful Face? 2What Would Women Give Up for a More Youthful Face? 3Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6
(Date:8/1/2015)... , ... August 01, 2015 , ... On Tuesday, July ... , who are thought to have been behind the attack on Anthem Inc. which ... were zero day exploits, watering hole attacks and spear phishing campaigns. , ...
(Date:8/1/2015)... ... ... March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery ... off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles ... by friends and family. He visited CCAR and left an inspirational message to his ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... The Honor ... Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San ... to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently ... know in predictive health analytics , Jvion continues to disrupt the predictive ... predictive software that targets patient and population level illness to drive prevention and ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being ... meal, making July the most appropriate to be National Hot Dog Month. King Kullen ... the next cookout different than the ones in the past. Celebrate National Hot Dog ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... plays a surprising role reducing the level of infection caused ... cancer patients and others with weakened immune systems. The ... fungal evaders by enhancing the body,s ability to chew them ... where it would continue to provoke an onslaught of harmful ...
... August 19, 2010The first successful report of using cell-depleted lung ... from embryonic stem cells is presented in a breakthrough article ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). The ... Embryonic stem cells (ESCs) have the potential to mature into ...
... doctoral student Lisa Carter-Harris has received the Johnson & ... Colleges of Nursing Minority Nursing Faculty Scholarship for the ... to graduate nursing students from minority backgrounds who agree ... , The AACN will hold $1,500 to cover expenses ...
... A recent study by researchers at Penn State College of ... lupus erythematosus (SLE) patients at the time of hospital admission ... women were youngest to both be admitted with CVD and ... the study appear in the September issue of Arthritis ...
... Reporter , WEDNESDAY, Aug. 18 (HealthDay News) -- Fibromyalgia sufferers ... tai chi, new research finds. Researchers divided 66 people ... of tai chi twice a week for 12 weeks; the ... stretching. At the end of 12 weeks, the ...
... A team of University of Michigan scientists has found ... roundworms. Scientists who study aging have long known that significantly ... is to find less drastic ways to achieve the same ... evidence that scientists may succeed at finding targets for drugs ...
Cached Medicine News:Health News:Old drug holds promise against opportunistic lung bug 2Health News:Old drug holds promise against opportunistic lung bug 3Health News:Old drug holds promise against opportunistic lung bug 4Health News:Natural lung material is promising scaffold for engineering lung tissue using embryonic stem cells 2Health News:UofL student wins national minority nursing scholarship 2Health News:Black women with SLE develop cardiovascular disease at early age 2Health News:Black women with SLE develop cardiovascular disease at early age 3Health News:Tai Chi May Help Ease Fibromyalgia 2Health News:Tai Chi May Help Ease Fibromyalgia 3Health News:Discovery may aid search for anti-aging drugs 2Health News:Discovery may aid search for anti-aging drugs 3
... many patients with a diseased heart, the only therapy ... heart transplant. However, donor organs are not always readily ... they are on the waiting list for a donor ... can save the life of a patient. On the ...
... InstaTest AFP is an immunochromatographic in ... protein (AFP) in human serum. AFP is ... 67,000 to 74,000 D. Its normal concentration ... concentrations are associated with hepatoma and ovarian, ...
... STA Compact is a ... coagulation analyser for clotting, ... based .coagulation tests.The medium-throughput ... of primary tubes, 45 ...
... Our high-quality MPD Lancets are designed with ... the tri-bevel, thin gauge needle with its ... smoother, less painful penetration without tearing the ... body is easy to grip, even for ...
Medicine Products: